Biostax (BTAX) Stock Price

Biostax Price

OTC·CLOSED
0.00
​
Market closed

Revenue has compounded at 91.3% per year over the past 3 years to 113,500.00 USD. Biostax's net margin stands at -7,202.8%, up from -87,916.7% several years earlier.

Biostax stock price

Access this data via the Eulerpool API

Biostax business model & stock analysis

Immune Therapeutics, Inc. engages in the development and marketing of pharmaceutical, biotechnology, and MedTech products. The company is headquartered in Winter Park, Florida. The company went IPO on 2001-07-16. Biostax has partnerships in the fields of autoimmunity and immune restoration, which focuses on delivering solutions for people living with autoimmunity, chronic inflammation, infection, and cancer. Its subsidiary BiostaxRx, is focused on the treatment of inflammaging disease. Its product portfolio includes Londonal, JKB-122 and Low Dose Naltrexone. Lodonal is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). JKB-122 is a therapy developed for the purposes of treating Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that shows anti-fibrotic, immune modulating, and/or anti-inflammatory effects.

Frequently asked questions about Biostax

Converted at the current exchange rate, the Biostax share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Biostax.

The profit cannot currently be calculated for Biostax.

The P/E ratio cannot be calculated for Biostax at the moment.

The P/S cannot be calculated for Biostax currently.

The Eulerpool Quality Score for Biostax is 2/10.

The ISIN of Biostax is US45252A3059. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Biostax is BTAX. The ticker symbol is used to trade Biostax shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 16, 2001
ISIN
US45252A3059
Cusip
45252A305
Market capitalization
15,742.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
73.84 %
Last updated Oct 9, 2026, 2:21 AM

Biostax Peer Group

Biostax Ticker

OTC · IMUN

Biostax FIGI

BTAX:US · BBG000DF3JV2IMUN:PQ · BBG000DF5TZ4BTAX:UV · BBG000DF5WC2IMUNGBP:XH · BBG00KXMY8N0IMUNGBP:XF · BBG00KXMY8Q7IMUNGBP:XE · BBG00KXMY8S5IMUNGBP:XL · BBG00KXMY8V1IMUNGBP:XG · BBG00KXMY8W0IMUNGBP:XO · BBG00KXMY8X9IMUNGBP:XA · BBG00KXMY921IMUNGBP:XT · BBG00KXMY949IMUNGBP:XW · BBG00KXMY958

All fundamentals and in-depth analysis of Biostax

Our stock analysis for Biostax stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biostax. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.